[呆住]_老虎社区_美港股上老虎

P20
2021-03-09

[呆住]

Pfizer/BioNTech COVID-19 vaccine neutralizes Brazil variant in lab study

NEW YORK, March 8 (Reuters) - The COVID-19 vaccine from Pfizer Inc and BioNTech SE was able to neutr

Pfizer/BioNTech COVID-19 vaccine neutralizes Brazil variant in lab study

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":329450765,"tweetId":"329450765","gmtCreate":1615272977957,"gmtModify":1703486558844,"author":{"id":3551107596978624,"idStr":"3551107596978624","authorId":3551107596978624,"authorIdStr":"3551107596978624","name":"P20","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[呆住]&nbsp;</span><br></p></body></html>","htmlText":"<html><head></head><body><p><span>[呆住]&nbsp;</span><br></p></body></html>","text":"[呆住]","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/329450765","repostId":2118923226,"repostType":4,"repost":{"id":"2118923226","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1615271378,"share":"https://www.laohu8.com/m/news/2118923226?lang=&edition=full","pubTime":"2021-03-09 14:29","market":"us","language":"en","title":"Pfizer/BioNTech COVID-19 vaccine neutralizes Brazil variant in lab study","url":"https://stock-news.laohu8.com/highlight/detail?id=2118923226","media":"Reuters","summary":"NEW YORK, March 8 (Reuters) - The COVID-19 vaccine from Pfizer Inc and BioNTech SE was able to neutr","content":"<p>NEW YORK, March 8 (Reuters) - The COVID-19 vaccine from Pfizer Inc and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> was able to neutralize a new variant of the coronavirus spreading rapidly in Brazil, according to a laboratory study published in the New England Journal of Medicine on Monday.</p>\n<p>Blood taken from people who had been given the vaccine neutralized an engineered version of the virus that contained the same mutations carried on the spike portion of the highly contagious P.1 variant first identified in Brazil, the study conducted by scientists from the companies and the University of Texas Medical Branch found.</p>\n<p>The scientists said the neutralizing ability was roughly equivalent the vaccine's effect on a previous less contagious version of the virus from last year.</p>\n<p>The spike, used by the virus to enter human cells, is the primary target of many COVID-19 vaccines.</p>\n<p>In previously published studies, Pfizer had found that its vaccine neutralized other more contagious variants first identified in the United Kingdom and South Africa, although the South African variant may reduce protective antibodies elicited by the vaccine.</p>\n<p>Pfizer has said it believes its current vaccine is highly likely to still protect against the South African variant. However, the drugmaker is planning to test a third booster dose of their vaccine as well as a version retooled specifically to combat the variant in order to better understand the immune response.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer/BioNTech COVID-19 vaccine neutralizes Brazil variant in lab study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer/BioNTech COVID-19 vaccine neutralizes Brazil variant in lab study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-09 14:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW YORK, March 8 (Reuters) - The COVID-19 vaccine from Pfizer Inc and <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a> was able to neutralize a new variant of the coronavirus spreading rapidly in Brazil, according to a laboratory study published in the New England Journal of Medicine on Monday.</p>\n<p>Blood taken from people who had been given the vaccine neutralized an engineered version of the virus that contained the same mutations carried on the spike portion of the highly contagious P.1 variant first identified in Brazil, the study conducted by scientists from the companies and the University of Texas Medical Branch found.</p>\n<p>The scientists said the neutralizing ability was roughly equivalent the vaccine's effect on a previous less contagious version of the virus from last year.</p>\n<p>The spike, used by the virus to enter human cells, is the primary target of many COVID-19 vaccines.</p>\n<p>In previously published studies, Pfizer had found that its vaccine neutralized other more contagious variants first identified in the United Kingdom and South Africa, although the South African variant may reduce protective antibodies elicited by the vaccine.</p>\n<p>Pfizer has said it believes its current vaccine is highly likely to still protect against the South African variant. However, the drugmaker is planning to test a third booster dose of their vaccine as well as a version retooled specifically to combat the variant in order to better understand the immune response.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE","PFE":"辉瑞"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2118923226","content_text":"NEW YORK, March 8 (Reuters) - The COVID-19 vaccine from Pfizer Inc and BioNTech SE was able to neutralize a new variant of the coronavirus spreading rapidly in Brazil, according to a laboratory study published in the New England Journal of Medicine on Monday.\nBlood taken from people who had been given the vaccine neutralized an engineered version of the virus that contained the same mutations carried on the spike portion of the highly contagious P.1 variant first identified in Brazil, the study conducted by scientists from the companies and the University of Texas Medical Branch found.\nThe scientists said the neutralizing ability was roughly equivalent the vaccine's effect on a previous less contagious version of the virus from last year.\nThe spike, used by the virus to enter human cells, is the primary target of many COVID-19 vaccines.\nIn previously published studies, Pfizer had found that its vaccine neutralized other more contagious variants first identified in the United Kingdom and South Africa, although the South African variant may reduce protective antibodies elicited by the vaccine.\nPfizer has said it believes its current vaccine is highly likely to still protect against the South African variant. However, the drugmaker is planning to test a third booster dose of their vaccine as well as a version retooled specifically to combat the variant in order to better understand the immune response.","news_type":1},"isVote":1,"tweetType":1,"viewCount":398,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}